Sarepta Therapeutics Inc
Change company Symbol lookup
Select an option...
SRPT Sarepta Therapeutics Inc
HXGBY Hexagon AB
XPO XPO Logistics Inc
TWO Two Harbors Investment Corp
VGI Virtus Global Multi-Sector Income Fund
GPOR Gulfport Energy Corp
GS Goldman Sachs Group Inc
VZ Verizon Communications Inc
XOM Exxon Mobil Corp
BA Boeing Co
Go

Health Care : Biotechnology | Mid Cap GrowthCompany profile

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD). It is focused on the development of its disease-modifying DMD drug candidates. It has received accelerated approval for its product, EXONDYS 51, indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. EXONDYS 51 is studied in clinical trials under the name of eteplirsen. Its next generation phosphorodiamidate morpholino oligomer (PMO)-based compounds are synthetic compounds that bind to complementary sequences of RNA by standard Watson-Crick nucleobase pairing. Its PMO-based chemistries are peptide conjugated PMO (PPMO), PMO-X and PMOplus.

Closing Price
$89.99
Day's Change
1.03 (1.16%)
Bid
--
Ask
--
B/A Size
--
Day's High
90.44
Day's Low
88.31
Volume
(Light)
Volume:
811,866

10-day average volume:
1,235,909
811,866
  • Prev Close
    88.96
  • Today's Open
    89.39
  • Day's Range
    88.31-90.44
  • Avg Vol (10-day)
    1.2M
  • Last (time)
    4:00p ET 05/24/18
  • Last (size)
    2.4K
  • 52-Wk Range
    28.82 - 95.67
    LowHigh
  • (05/31/17 - 05/16/18)
    5.94%
  • 48.8%
  • Market Cap
    5.9B
  • Shares Outstanding
    65.5M
  • -2.85
  • --
  • No dividend
  • Ex-dividend
    No dividend
  • 1.3
  • 84.66
  • (% of float 04/30/18)
    16.18

Latest News

May 07, 2018
7:30 am ET
PR Newswire
May 03, 2018
4:57 pm ET
MarketWatch
4:01 pm ET
Globe Newswire
4:01 pm ET
Globe Newswire
April 30, 2018
6:00 pm ET
Globe Newswire
April 27, 2018
7:38 am ET
Globe Newswire
April 23, 2018
8:30 am ET
Globe Newswire
March 30, 2018
6:00 pm ET
Globe Newswire
March 20, 2018
8:30 am ET
Globe Newswire
March 16, 2018
8:16 am ET
MarketWatch
6:30 am ET
PR Newswire
March 12, 2018
7:49 am ET
MarketWatch
7:43 am ET
MarketWatch
7:30 am ET
Globe Newswire
March 02, 2018
12:33 pm ET
MarketWatch
March 01, 2018
4:18 pm ET
MarketWatch
4:10 pm ET
MarketWatch
4:09 pm ET
MarketWatch
4:09 pm ET
MarketWatch
4:08 pm ET
MarketWatch
4:01 pm ET
Globe Newswire
February 28, 2018
6:00 pm ET
Globe Newswire
February 27, 2018
8:30 am ET
Globe Newswire
February 09, 2018
10:08 am ET
MarketWatch
9:50 am ET
MarketWatch
January 14, 2018
2:18 pm ET
MarketWatch
January 13, 2018
12:22 pm ET
MarketWatch
August 07, 2017
6:10 am ET
PR Newswire
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2018 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2018. All rights reserved.